Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.570
-0.020 (-1.26%)
At close: Nov 25, 2025, 4:00 PM EST
1.589
+0.019 (1.23%)
After-hours: Nov 25, 2025, 6:40 PM EST
Akebia Therapeutics Revenue
Akebia Therapeutics had revenue of $58.77M in the quarter ending September 30, 2025, with 57.01% growth. This brings the company's revenue in the last twelve months to $225.07M, up 32.49% year-over-year. In the year 2024, Akebia Therapeutics had annual revenue of $160.18M, down -17.70%.
Revenue (ttm)
$225.07M
Revenue Growth
+32.49%
P/S Ratio
1.71
Revenue / Employee
$1,243,486
Employees
181
Market Cap
416.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
| Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
| Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
| Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
| Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AKBA News
- 1 day ago - Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 15 days ago - Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 19 days ago - Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs - GlobeNewsWire
- 21 days ago - Akebia Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights - GlobeNewsWire
- 27 days ago - FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug - Benzinga